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Abstract
Background: Various cytokines and inflammatory mediators are known to be involved in the pathogenesis of
rheumatoid arthritis (RA). We hypothesized that polymorphisms in selected inflammatory response and tissue repair
genes contribute to the susceptibility to and severity of RA.
Methods: Polymorphisms in TNFA, IL1B, IL4, IL6, IL8, IL10, PAI1, NOS2a, C1INH, PARP, TLR2 and TLR4 were genotyped
in 376 Caucasian RA patients and 463 healthy Caucasian controls using single base extension. Genotype
distributions in patients were compared with those in controls. In addition, the association of polymorphisms with
the need for anti-TNF-a treatment as a marker of RA severity was assessed.
Results: The IL8 781 CC genotype was associated with early onset of disease. The TNFA -238 G/A polymorphism
was differentially distributed between RA patients and controls, but only when not corrected for age and gender.
None of the polymorphisms was associated with disease severity.
Conclusions: We here report an association between IL8 781 C/T polymorphism and age of onset of RA. Our
findings indicate that there might be a role for variations in genes involved in the immune response and in tissue
repair in RA pathogenesis. Nevertheless, additional larger genomic and functional studies are required to further
define their role in RA.
Background
Rheumatoid arthritis (RA) is a severely disabling chronic
inflammatory disease that affects millions of people
worldwide. Like in other autoimmune diseases females
are affected more often than males. The disease course
differs widely between patients. While some have low
grade disease which is easily controlled by therapy with
one disease-modifying anti-rheumatic drug (DMARD),
others suffer from rapidly progressive disease with ero-
sions that is therapy resistant, resulting in the use of
many different DMARDs or even the need for therapy
with the new biologicals directed against TNF-a. Cyto-
kines and other proteins involved in the inflammatory
response play a role in RA. Pro-inflammatory cytokines
such as TNF-a and IL-1b are regarded as key players in
the pathogenesis of RA [1,2]. This is further underlined
by the development of several anti-cytokine drugs in the
treatment of RA, with anti-TNF monoclonal antibodies
and soluble TNF-a receptor being the most effective.
TNF-a is an important pro-inflammatory cytokine. IL-
1b in its turn, stimulates expression of IL-6 and IL-8
[2]. Since IL-8 is involved in the initiation and amplifica-
tion of acute inflammatory responses and in chronic
inflammation, genetic variations (indirectly) linked to
alterations in expression could be associated to RA sus-
ceptibility or severity[3-5]. Antibodies directed against
the IL-6 receptor are effective in the treatment of RA
[6]. IL-4 and IL-10 on the other hand, have been sug-
gested to ameliorate arthritis [7,8]. Deficiency of IL-4 is
associated with increased severity of arthritis in a mouse
model[9]. In addition, the V50 variant in the IL-4 recep-
tor causing unresponsiveness to IL-4, is associated with
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rapidly erosive RA [10]. In addition to inflammatory tis-
sue destruction, factors involved in tissue repair and
necrosis or apoptosis are likely to be involved in erosive
disease and may also codetermine disease susceptibility.
Plasminogen activator inhibitor 1 (PAI-1) inhibits fibri-
nolysis and tissue repair [11,12]. Plasminogen deficiency
is associated with decreased susceptibility to and severity
of arthritis in mice models for RA [13]. Previously the
influence of genetic polymorphisms in inflammatory dis-
eases such as RA has become evident. The association
with the HLA DRB1 locus is the best characterized and
replicated [14,15]. Linkage studies in RA families and
genome wide screening in case control studies have
identified over 30 validated additional genetic loci asso-
ciated with RA such as HLADRB1, PTPN22, TNFAIP3,
TRAF1, STAT4, CCR6, PXK, 10p15,12q13 and 22q13
[14,16-23]. For a recent overview we refer to the review
of Orozco and Barton [24]. We used the classic candi-
date gene approach, including immune response factors
that had previously been shown to be involved in RA
pathogenesis, or were likely to be involved. This
approach increases the chance that when a SNP is
found to be significantly associated with disease, it may
actually be the functional SNP. However, the relatively
small sample size does limit the chance of finding loci
of modest effect size and confirmation in independent
cohorts is required. The SNPs in the genes were
selected on the basis of either a functional effect, both
on transcription (e.g. PAI1, IL6, IL10, IL4, IL1B) and
amino acid substitution, resulting in functional differ-
ences (e.g. PARP) [25-32]. In addition, polymorphisms,
such as in TNFA and IL8, previously associated with RA
or other inflammatory diseases were considered relevant
as well, even if they were positioned in an intron
[3,33-35].
Therefore, in this study including 376 RA patients and
463 controls, we investigated the possible association of
polymorphisms in immune response genes (TNFA,
IL1B, IL4, IL6, IL8, IL10, C1INH, TLR2, TLR4) and
genes involved in tissue repair and apoptosis (PAI1,
5NOS2a, PARP) in relation to RA susceptibility, and




Non related Caucasian patients who met the 1987 ACR
criteria for RA and visited the rheumatology outpatient
clinic of the Erasmus MC university hospital (n = 76),
the Medical Center Rijnmond Zuid (n = 195) or the St.
Franciscus Gasthuis Hospital (n = 105), in 2005 were
included in the study. Additionally, the patients had to
have at least either a positive rheumatoid factor test, or
a positive anti-CCP test, or joint erosions. The study
was approved by the medical ethical boards of the Eras-
mus MC and participating hospitals: Medical Center
Rijnmond Zuid and the St. Franciscus Gasthuis Hospital.
Patients were included after written informed consent.
Gender, age at inclusion in the study, age at diagnosis,
clinical parameters and current and prior medication
were derived from the clinical charts.
Since in The Netherlands treatment of RA is strictly
aimed at achieving clinical remission, disease activity itself
cannot be used as a marker for disease severity. For that
reason it was chosen to use the need for therapy with anti-
TNF as an alternative marker for disease severity. This can
be done reliably since in the Netherlands the prescription
of anti-TNF is strictly regulated and the costs for anti-TNF
treatment are only reimbursed by the health insurance
companies for RA-patients with therapy-resistant disease.
Therapy-resistance is defined as failure of at least two dis-
ease-modifying anti-rheumatic drugs (DMARDs) including
methotrexate, and still active disease (defined as DAS28 >
3.2) despite therapy with methotrexate 25 mg weekly or
with methotrexate at the maximum tolerated dose. Blood
was drawn for DNA isolation and routine laboratory analy-
sis. Since the anti-CCP test has only recently been intro-
duced into routine patient care, only for a minority of
patients (n = 125) anti CCP status was known.
Caucasian controls representing the general adult
population (n = 463) were derived from the Sanquin
Blood Bank South West Region.
Experimental procedures
DNA isolation
For RA patients DNA isolation from heparinized whole
blood was performed as described previously [36]. DNA
from controls was derived from whole blood with col-
umn methods using standard protocols (Qiagen, Leus-
den, The Netherlands).
Genotyping
Single base extension (SBE) analysis was used to deter-
mine genotypes of inducible nitric oxide synthase
(NOS2A) S608L (rs2297518), poly (ADP-ribose) poly-
merase (PARP) V762A (rs1136410), complement com-
ponent inhibitor-1 (C1INH) V480 M (rs4926), PAI1
-675 4G/5G (rs1799889), IL4 C-524T (rs2243250), IL10
G-1082A (rs1800896), IL10 C-819T (rs3021097), IL1B
C-31T (rs1143627), TNFA A-863C (rs1800630), TNFA
T-857C (rs1799724), TNFA G-376A (rs3093659),
TNFA G-308A (rs1800629), TNFA G-238A (rs361525),
IL6 G-174C (rs1800795), IL8 C781T intron
(rs2227306), TLR4 D299G (rs4986790) and TLR4
T399I (rs4986791) http://www.ncbi.nlm.nih.gov/SNP/,
Applied Biosystems, SNaPShot, standard protocol as
supplied by the manufacturer, Nieuwerkerk aan den
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IJssel, The Netherlands). The genomic region of inter-
est was amplified by PCR (Additional file 1: Table S1,
S2, and S3). After purification, a single base extension
was performed using a primer ending one nucleotide
prior to the single nucleotide polymorphism (SNP)
location. Both forward and reverse strands were tested.
In a multiplex assay one of the primers was used to
genotype the SNP of interest. Up to seven SNPs were
analysed in one assay. A poly-T-tail attached to the
primer combined with the use of a Liz size marker
served to distinguish SNPs in the multiplex analysis
(Additional file 1: Table S4). A subset of PCR samples
was sequenced to confirm genotypes. All genotypes
were annotated independently by two investigators
who were blinded for the clinical data.
Statistical analysis
Statistical analysis was performed using SPSS 11.5. Hap-
lotype analysis was carried out with Thesias version 2
[37,38]. Genotype frequencies were compared between
patients with RA and controls using the Cochrane-
Armitage trend test for additive effects. The median
number of different drugs used per year since the
moment of diagnosis was assessed. Additionally, geno-
type distributions between patients who received anti-
TNF-a medication were compared with those who did
not. Binomial variables were analysed using Pearson’s
chi-square test (2df) or Fisher’s exact test when appro-
priate. For continuous variables Student’s T test or
Mann-Whitney U test were used when appropriate.
Verification of Hardy Weinberg equilibrium (HWE) of
genotypes was performed using Chi-square test (1df).
Probability (P) values < 0.05 were considered to be sta-
tistically significant. Significant probability values
obtained were corrected for multiple testing using Bon-
ferroni for the number SNPs tested (n = 17) and the
number of tests performed (n = 3). Power calculations
using Quanto revealed a power of 0.8 to detect an OR
of 1.5 comparing patients and controls given an allele
frequency of 0.1 and a of 0.05 [39].
Results
Patient characteristics
376 patients, mean age (sd) 59.3 years (13.7) and 463
controls mean age (sd) 39.1 years (8.5), were included in
the study (p < 0.001). In the patient and control cohort
277 (73.7%) and 230 (49.7%) individuals were female,
respectively (p < 0.001). All patients were included when
comparing RA patients with healthy controls. For
6 patients records regarding medication use were
incomplete due to (multiple) transfers of patients from
other hospitals. For this reason the 370 patients for
whom medication data was complete were included in
the analysis regarding disease severity (Table 1).
Genotypes and disease susceptibility
In controls, genotype distribution of all SNPs except the
IL10 G-819A polymorphism reached Hardy Weinberg
Equilibrium (HWE). To rule out a technical problem, an
initial set of individuals was typed using both the reverse
and forward primer in the single base extension reaction.
Results for both strands were identical. Sequencing of a
subset of 13 random controls showed identical genotypes
excluding technical errors (data not shown). When
Bonferroni correction is applied, none of the SNPs was
significantly associated with RA susceptibility, adjusted
for age and gender. Using the Cochrane-Armitage trend
test for additive effects an association was observed for
the TNFA -238 G/A polymorphisms (Bonferroni cor-
rected p values 0.04). The TNFA-238 G/G genotype were
overrepresented in RA patients when compared to con-
trols (crude OR (95% CI) 2.48 (1.38-4.46) for TNFA G/G
vs G/A; Table 2). Analysis of TNFA haplotypes yielded
similar results as for the individual SNPs (data not
shown). Since RA patients were significantly older than
healthy controls and controls are by definition still ‘at
risk’ to develop RA at a later age, the difference observed
may also result from a difference in susceptibility to
develop RA at a younger age. For this reason the relation
of all SNPs with the age at diagnosis was analysed. The
IL8 781 C/C genotype was associated with younger age at
RA diagnosis compared to both the IL8 781 C/T and T/T
genotype (mean age (SD): IL8 781 T/T 52.2 (14) years, T/
C 50.0 (14) years and C/C 44.2 (13) years, respectively,
p < 0.01, after Bonferroni correction; Table 3).
Genetic polymorphisms and severity of disease
The use of TNF-a modifying therapy was considered to
be an indicator of severe disease in the Dutch situation
as explained in the methods section. Anti-TNF-a drugs
were administered to 120 of 370 patients. The mean age
(sd) of patients who used anti-TNF-a was 55.7 (12.8)
years compared with 60.8 (13.9) years in the group that
did not receive anti-TNF-a (p = 0.001). Presence of anti
CCP antibodies, RF or disease duration was not different
between the two groups. In contrast, the presence of
erosions, and the numbers of DMARDs used was differ-
entially distributed between patients requiring anti-TNF
treatment to obtain acceptable disease activity and those
who did not (Table 1). Only a trend was observed for
the TNFA -308 G/A polymorphism using the Cochrane-
Armitage trend test for additive effects (p = 0.04, with-
out Bonferroni correction). After adjustment for age and
multiple testing, none of the polymorphisms was signifi-
cantly associated with disease severity (Table 4).
Discussion
In our study the IL8 781 C/C genotype was associated
with a younger age at RA diagnosis. Increased IL-8
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expression was associated with RA when compared
with osteoarthritis [40]. The IL8 C/T polymorphism
was previously associated with viral infection, but no
data are available on the effect of this intronic poly-
morphism on IL-8 expression. Recently a group in
Taiwan published the IL-8 3’-UTR 2767AA genotype
to be associated with younger age at onset [41]. The
IL8 781C, IL8 276A and the IL8 -251T alleles appear
to be in linkage disequilibrium [3]. The IL8 -251
T allele has previously been associated with respiratory
syncytial virus infection in children, in whom also
higher serum IL-8 levels were observed [3]. Given the
role of IL-8 in promoting the pro-inflammatory
response this could explain the association of IL8 poly-
morphisms with early onset of RA.
Only the TNFA -238 polymorphism was differentially
distributed between RA patients and controls, even after
Bonferroni correction. However, after adjustment for
age and gender none remained significant. Using anti-
TNF requirement as marker for severity a trend was
observed for the TNFA -238 polymorphism. The find-
ings for the TNFA-238 polymorphism match those
reported for both a Mexican and a Colombian cohort
[33,35]. Additionally, in the Mexican cohort, the -308 A
allele was associated with more severe disease, while it
is also reported to be associated with erosion in RA
patients [35,42]. Moreover, carriage of the TNFA -308A
allele, related to higher TNF-a production, was pre-
viously reported to be associated with non-response to
anti-TNF-a in patients with different autoimmune dis-
eases among which RA [43-45]. In the past numerous
studies have been performed to investigate the associa-
tion of TNFA promoter polymorphisms and TNF-a
levels in different inflammatory and infectious diseases,
reporting contradictory results [46]. TNF-a expression
is probably not determined by one but by a combination
of polymorphisms in TNFA and -associated genes. In
our study, and in contrast to those described above,
only the TNFA -238A allele showed a trend towards
more severe disease (Table 3). It must however be noted
that the allele frequency is very low and a slight differ-
ence in genotype distribution would markedly alter the
results. Moreover, it is not unlikely that the observations
for the TNFA polymorphisms result at least in part from
Table 1 Patient characteristics
Total Treatment
RA patients n = 370 No anti-TNF n = 370 Anti-TNF
n = 120
p
Mean age (sd) 59.1 (13.7) 60.8 (13.9) 55.7 (12.8) 0.001
Female gender (%) 272 (73.5) 177 (71) 95 (79) 0.10
Median nr years with RA (min-max) 8.5 (0-54) 8.7 (0-54) 8.3 (0-46) 0.13 (MW)
Anti-CCP positive (%)a 104/125 (83.2) 75/90 (83) 29/35 (83) 1.0
Reumatoid factor positive (%) 337/369 (91.3) 228 (91) 109/119 (92) 1.0
Erosion (%) 291/357 (81.5) 189/243 (78) 102/114 (90) 0.008
Geometric mean number of DMARDs (95% CI) 2.96 (2.79-3.13) 2.37 (2.22-2.52) 4.69 (4.41-4.99) < 0.001
Geometric mean DMARDs per disease year (95% CI) 0.42 (0.37-0.47) 0.37 (0.31-0.43) 0.55 (0.47-0.64) 0.001
Number of patients with current or past use of DMARDs (%)
Methotrexate 331 (89.5) 212 (85) 119 (99) < 0.001
Salazopyrine 262 (70.8) 162 (65) 100 (83) < 0.001
Antimalaria 176 (47.6) 105 (42) 71 (59) 0.003
Leflunomide 33 (8.9) 16 (6) 17 (14) 0.02
Intramuscular gold 55 (14.9) 36 (14) 19 (16) 0.76
Infliximab 35 (9.5) 0 35 (29) < 0.001
Etanercept 61 (16.5) 0 61 (51) < 0.001
Adalilumab 60 (16.2) 0 60 (50) < 0.001
Anakinra 14 (3.8) 2 (1) 12 (10) < 0.001
Oral corticosteroids 164 (44.3) 103 (41) 61 (51) 0.09
Azathioprine 33 (8.9) 13 (5) 20 (17) 0.001
Others
n = 1 32 (8.6) 17 (6.8) 15 (12.5) 0.01
n = 2 5 (1.4) 1 (0.4) 4 (3.3)
aAnti-CCP was not routinely analyzed.
MW: Mann Witney.
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linkage disequilibrium with the HLADRB1 locus, which
was previously associated with RA [14,15,19].
No association of polymorphisms with disease severity
was observed after correction for multiple testing. Many
would argue that functional studies are preferred over
genetic association studies. However, interpretation of
RNA expression analyses is difficult due to the intra and
inter-patient variation [47]. Careful sampling may over-
come this problem and reduce the finding of false posi-
tive differentially expressed genes. With the exception of
those studies assessing cytokine expression only in
patients without DMARDs at diagnosis, results are likely
to be influenced by the use of these DMARDs and dis-
ease progression. For this reason comparison of the
results of different studies is limited. One can question
whether therapy with anti-TNF is an appropriate marker
for disease severity. In the modern era of aggressive
treatment of RA medication is intensified till the goal of
low disease activity or even remission is achieved. That
disease activity was low is underscored by the low
Table 2 Genotype frequencies in RA patients and controls










C/C 82 (17.9) 56 (16.7) 0.01 G/G 301 (65.2) 254 (68.6) 0.22
C/G 231 (50.3) 133 (39.7) G/A 140 (30.3) 104 (28.1)
G/G 146 (31.8) 146 (43.6) A/A 21 (4.5) 12 (3.2)
IL8 781 PARP 762
C/C 152 (32.9) 141 (37.5) 0.4 T/T 299 (66.6) 261 (70.7) 0.40
C/T 234 (50.6) 171 (45.5) T/C 140 (31.2) 96 (26.0)
T/T 76 (16.5) 64 (17.0) C/C 10 (2.2) 12 (3.3)
PAI1 4/5G IL4-524
5G/5G 99 (21.4) 101 (27.7) 0.12 C/C 339 (73.7) 267 (71.8) 0.30
5G/4G 240 (51.9) 172 (47.1) C/T 112 (24.3) 91 (24.5)
4G/4G 123 (26.6) 92 (25.2) T/T 9 (2.0) 14 (3.8)
TNFA-863 C1INH 480
C/C 329 (71.4) 239 (64.8) 0.16 G/G 255 (55.4) 211 (58.3) 0.47
C/A 117 (25.4) 123 (33.3) G/A 176 (38.3) 129 (35.6)
A/A 15 (3.3) 7 (1.9) A/A 29 (6.3) 22 (6.1)
TNFA-857 Il10-1082
C/C 386 (84.5) 314 (86.5) 0.29 G/G 123 (26.8) 88 (24.7) 0.77
C/T 66 (14.4) 48 (13.2) G/A 219 (47.7) 172 (48.3)
T/T 5 (1.1) 1 (0.3) A/A 117 (25.5) 96 (27)
TNFA-376 IL10-819
G/G 446 (96.7) 371 (98.9) 0.04 C/C 283 (61.5) 233 (63.7) 0.99
G/A 15 (3.3) 4 (1.1) C/T 145 (31.5) 100 (27.3)
A/A T/T 32 (7.0) 33 (9.0)
TNFA-308 TLR4 299
G/G 300 (65.1) 248 (66.1) 0.60 A/A 373 (86.3) 315 (85.1) 0.62
G/A 147 (31.9) 119 (31.7) A/G 58 (13.4) 54 (14.6)
A/A 14 (3.0) 8 (2.1) G/G 1 (0.2) 1 (0.3)
TNFA-238 TLR4 399
G/G 415 (90.0) 359 (95.7) 0.002 C/C 378 (87.1) 314 (84.9) 0.42
G/A 46 (10.0) 16 (4.3) C/T 54 (12.4) 55 (14.9)
A/A T/T 2 (0.5) 1 (0.3)
IL1B-31
C/C 57 (12.5) 48 (12.8) 0.62
C/T 214 (46.9) 165 (44.0)
T/T 185 (40.6) 162 (43.2)
a Cochrane-Armitage trend test for additive effects; p value represents analysis not corrected for multiple testing. When Bonferroni correction is applied (factor
20 for the number of SNPs (17) and tests (3)) only the TNFA-238 polymorphism remains significant (p = 0.04).
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geometric mean ESR level in our cohort of RA-patients
(16.2; 95% CI 14.7-17.7 mm/hr), that was not different
(p = 0.17) between patients on conventional DMARDs
(15.4; 95% CI 13.8-17.3 mm/hr) or those on biologicals
(17.6; 95% CI 15.1-20.5 mm/hr). It was therefore
decided not to use disease activity as marker of disease
severity, but whether low disease activity could be
achieved by conventional DMARDs or by use of biologi-
cals directed against TNF. That therapy with a biological
against TNF could be used as a marker of disease
severity in this study is also due to the fact that its use
is strictly regulated in the Netherlands; therapy with bio-
logicals against TNF is available for all RA-patients that
failed on two DMARDs and still have active disease
(DAS28 > 3.2) despite therapy with methotrexate 25 mg
weekly or at the maximal tolerated dose.
No association was observed for the IL10 polymorph-
isms with RA susceptibility or severity. Previously, con-
trasting results were reported for the role of IL10
polymorphisms in RA [48-50]. A recent study demon-
strated a significant association between having RA and
the IL10 1082 G allele (p = 0.008; OR = 1.44, 95% CI
1.11-1.86) [50]. Recently, a substantial improvement of
RA upon treatment with anti-IL-6 receptor antibody [6].
The IL6 G/G genotype is associated with increased IL-6
levels compared to the C/C genotype, contributing to
the complex regulation of IL-6 production [26,51-53].
Furthermore, IL-6 expression in synovial tissue is higher
in end-stage RA than in chronic active RA [54]. IL-6
expression is influenced by TNF-a, and interaction of
polymorphisms in these and other genes may co-deter-
mine the disease phenotype. This interaction in combi-
nation with the limited sample size may have prohibited
finding an association of the IL6 polymorphism with
RA.
Although a polymorphism in TLR4 has previously
been associated with rapid response to treatment in RA
no association with RA was observed for the TLR4 poly-
morphisms in our study [55].
Recent GWAS studies on RA susceptibility included
thousands of patients. We used a candidate gene
approach in the SNP selection because this is a moder-
ately sized population. Despite having a larger a priori
chance of finding a true association if SNPs are asso-
ciated with disease, this may have resulted in both false
positive and false negative findings. The recent studies
observed no larger effect size than an OR of approxi-
mately 1.3. This implies that our study is probably
underpowered to detect loci with a modest effect, and
that larger patient numbers are needed to gain further
insight into the possible role of these genes in RA
pathogenesis. Additionally, apart from the TNFA region,
the identified genomic regions of interest in these
GWAS study do not correspond to the location of the
genes we selected. Nevertheless, although validation of
our results in an independent cohort is required, the
data presented here do remain valuable for meta-
analysis.
Conclusions
In summary we here report an association between
IL8 781 C/T polymorphism and a younger age of
Table 3 Age of onset of RA in relation to genotypes
SNP Age of onset p SNP Age of onset p
Mean (SD) Mean (SD)
IL6-174 NOS2a 608
C/C 48 (11) 0.16 G/G 47 (13) 0.10
C/G 50 (15) G/A 51 (15)
G/G 47 (15) A/A 49 (17)
IL8 781 PARP 762
C/C 44 (13) < 0.0001 T/T 48 (14) 0.44
C/T 50 (14) T/C 48 (15)
T/T 52 (14) C/C 53 (13)
PAI1 4/5G IL4-524
5G/5G 46 (15) 0.22 C/C 48 (14) 0.48
5G/4G 49 (13) C/T 50 (14)
4G/4G 49 (14) T/T 49 (16)
TNFA-863 C1INH 480
C/C 48 (14) 0.40 G/G 48 (14) 0.41
C/A 48 (13) G/A 48 (15)
A/A 55 (20) A/A 52 (12)
TNFA-857 Il10-1082
C/C 49 (14) 0.75 G/G 49 (14) 0.90
C/T 48 (14) G/A 48 (14)
T/T 38 (-) (n = 1) A/A 148 (14)
TNFA-376 IL10-819
G/G 48 (14) 0.01 C/C 49 (14) 0.10
G/A 30 (14) C/T 46 (14)
A/A T/T 49 (14)
TNFA-308 TLR4 299
G/G 48 (14) 0.69 A/A 48 (14) 0.86
G/A 49 (14) A/G 48 (13)
A/A 52 (14) G/G 56 (-)(n = 1)
TNFA-238 TLR4 399
G/G 48 (14) 0.40 C/C 48 (14) 0.82
G/A 45 (15) C/T 49 (14)
A/A T/T 56 (-)(n = 1)
IL1B-31
C/C 47 (15) 0.84
C/T 48 (15)
T/T 48 (13)
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onset of RA. After correction for age (and gender),
and multiple testing, none of the polymorphisms was
associated with RA susceptibility or severity. This
illustrates the need for additional larger studies to
elucidate the contributing factor of polymorphisms in
the susceptibility to and severity of RA. Carefully
designed functional studies regarding expression
of mRNA and protein levels in combination with
genetic analyses are warranted to elucidate the contri-
bution of polymorphisms to disease severity and
will contribute to improving our knowledge on RA
pathogenesis.
Table 4 Comparison of genotype frequencies between RA patients with or without anti-TNF therapy, as marker of
disease severity
SNP Genotype frequency p trenda SNP Genotype frequency p trenda
No anti-TNF Anti-TNF No anti-TNF Anti-TNF
250 n (%) 120 n (%) 250 n (%) 120 n (%)
IL6-174 NOS2a 608
C/C 33 (15.1) 22 (19.8) 0.06 G/G 175 (70.9) 75 (64.1) 0.18
C/G 83 (37.9) 49 (44.1) G/A 65 (26.3) 37 (31.6)
G/G 103 (47.0) 40 (36.0) A/A 7 (2.8) 5 (4.3)
IL8 781 PARP 762
C/C 97 (38.8) 43 (35.8) 0.92 T/T 180 (73.2) 75 (64.1) 0.37
C/T 108 (43.2) 58 (48.3) T/C 55 (22.4) 41 (35.0)
T/T 45 (18.0) 19 (15.8) C/C 11 (4.5) 1 (0.9)
PAI1 4/5G IL4-524
5G/5G 67 (27.6) 33 (28.4) 0.97 C/C 177 (71.7) 87 (73.1) 0.62
5G/4G 116 (47.7) 53 (45.7) C/T 60 (24.3) 29 (24.4)
4G/4G 60 (24.7) 30 (25.9) T/T 10 (4) 3 (2.5)
TNFA-863 C1INH 480
C/C 155 (62.8) 78 (67.2) 0.42 G/G 143 (58.8) 65 (57.5) 0.62
C/A 87 (35.2) 36 (31.0) G/A 82 (33.7) 45 (39.8)
A/A 5 (2.0) 2 (1.7) A/A 18 (7.4) 3 (2.7)
TNFA-857 II10-1082
C/C 212 (87.2) 96 (84.2) 0.52 G/G 61 (25.7) 25 (21.9) 0.55
C/T 30 (12.3) 18 (15.8) G/A 112 (47.3) 57 (50.0)
T/T 1 (0.4) A/A 64 (27.0) 32 (28.1)
TNFA-376 IL10-819
G/G 248 (99.2) 118 (98.3) 0.45 C/C 153 (63.2) 75 (63.6) 0.72
G/A 2 (0.8) 2 (1.7) C/T 65 (26.9) 34 (28.8)
A/A T/T 24 (9.9) 9 (7.6)
TNFA-308 TLR4 299
G/G 156 (62.4) 89 (74.2) 0.13 A/A 206 (83.7) 104 (88.1) 0.24
G/A 91 (36.4) 26 (21.7) A/G 39 (15.9) 14 (11.9)
A/A 3 (1.2) 5 (4.2) G/G 1 (0.4)
TNFA-238 TLR4 399
G/G 243 (97.2) 111 (92.5) 0.04 C/C 206 (83.7) 103 (87.3) 0.34
G/A 7 (2.8) 9 (7.5) C/T 39 (15.9) 15 (12.7)
A/A T/T 1 (0.4)
IL1B-31
C/C 30 (12.0) 17 (14.3) 0.68
C/T 116 (46.4) 46 (38.6)
T/T 104 (41.6) 56 (47.1)
Only patients for whom data regarding medication were complete (n = 370) were included.
a. Cochrane-Armitage trend test for additive effects. p value represents analysis not corrected for multiple testing. When Bonferroni correction is applied none of
the polymorphism tested remain significant.
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Additional material
Additional file 1: Supplemental tables S1, S2, S3 and S4.
Supplemental table S1. PCR primer sequences. Supplemental table S2.
PCR conditions using 384 Tetrad PCR machine. Supplemental table S3.
Touchdown protocols for PCR. Supplemental table S4. Primer sequences
for SBE reactions.
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